Noninferiority of Denosumab As Compared With Zolendronic Acid With Respect to the Ability to Delay Skeletal Events in Patients With Solid Tumors and Multiple Myeloma
b'By David Avigan. This podcast describes a phase III randomized study comparing the efficacy and toxicity of Denosumab with Zolendronic Acid for the prevention of skeletal complications in patients with malignancy.'